Pharmaceutical Moderna reported on Monday that its COVID-19 vaccine is proving highly effective in a larger trial, a second ray of hope in the global injection race to suppress a resurgent virus that is now killing more than 8,000 people. Daily.

The company said its vaccine appears to be 94.5 percent effective, according to preliminary data from the still-ongoing Moderna study. Rival Pfizer Inc. announced a week ago that its own COVID-19 vaccine was showing similar effectiveness – news that put the two companies on track to obtain approval for use within weeks in the United States.

The vaccine isn’t coming soon enough, as coronavirus cases topped 11 million in the United States over the weekend – one million of them recorded last week. The pandemic has killed more than 1.3 million people worldwide, including more than 245,000 in the United States.

Moderna chairman Doctor Stephen Hoge celebrated the “very important milestone”, although he noted that it is more reassuring that there are similar results from two different companies.

“It should give us all hope that a vaccine can really stop this pandemic and hopefully get us back into our lives,” Hoge told The Associated Press.

“It won’t just be Modern that solves this problem. It will take a lot of vaccines ”to meet global demand, he added.

However, if the US Food and Drug Administration (FDA) authorizes the emergency use of the Moderna or Pfizer vaccine candidates, supplies will be limited and rationed before the end of the year. Both vaccines require two people to receive two doses, spaced several weeks apart.

Moderna expects approximately 20 million doses to be destined for the United States by the end of 2020. Pfizer and its German partner BioNTech expect to have approximately 50 million doses worldwide by the end of 2020. end of the year.

The reaction from global equity markets was immediate. The Dow Jones doubled its gains before trading began and rose 500 points before the day. Moderna shares, which climbed 13%, are expected to hit all-time highs. The Asian and European markets also showed strong momentum.

Moderna’s vaccine, created in collaboration with the National Institutes of Health, is being studied in 30,000 volunteers who receive either the real vaccine or a dummy injection. On Sunday, an independent watchdog violated code to examine 95 infections that records show began two weeks after the volunteers’ second dose – and found that all but five of those illnesses occurred in participants who had received the placebo.

___

The Associated Press’s Department of Health and Science receives support from the Department of Science Education at the Howard Hughes Medical Institute. The AP is solely responsible for all its content.

Leave a Reply

Your email address will not be published. Required fields are marked *